Research Explorer

Your browser does not support JavaScript or JavaScript is not enabled. Without JavaScript some functions of this webapplication may be disabled or cause error messages. To enable JavaScript, please consult the manual of your browser or contact your system administrator.

Researcher

Anneleen Beckers

56 Results

2021

MEIS2 is an adrenergic core regulatory transcription factor involved in early initiation of TH-MYCN-driven neuroblastoma formation

Jolien De WynMark W. ZimmermanNina Weichert-LeaheyCarolina de Carvalho NunesBelamy B. CheungBrian J. AbrahamAnneleen BeckersPieter-Jan VoldersBieke DecaestekerDaniel R. Carter et al.

A1 Journal Article in CANCERS

2018

Network modeling of microRNA-mRNA interactions in neuroblastoma tumorigenesis identifies miR-204 as a direct inhibitor of MYCN

Chi Yan OoiDaniel R CarterBing LiuChelsea MayohAnneleen BeckersAmit LalwaniZsuzsanna NagySara De BrouwerBieke DecaestekerTzong-Tyng Hung et al.

A1 Journal Article in CANCER RESEARCH

The mutational landscape of MYCN, Lin28b and ALKF1174L driven murine neuroblastoma mimics human disease

Bram De WildeAnneleen BeckersSven LindnerKristina AlthoffKatleen De PreterPauline DepuydtPieter MestdaghTom SanteSteve LefeverFalk Hertwig et al.

A2 Journal Article in ONCOTARGET

2017

Targeting tachykinin receptors in neuroblastoma

Anton G HenssenAndrea OderskyAnnabell SzymanskyMarleen SeilerKristina AlthoffAnneleen BeckersFranki SpelemanSimon SchäfersKatleen De PreterKathy Astrahanseff et al.

A1 Journal Article in ONCOTARGET

2016

An embryonic stem cell activated FOXM1 transcriptional program marks ultra-high-risk primary neuroblastoma patients for FDI-6 small molecule inhibition

Suzanne VanhauwaertCarina LeonelliSara De BrouwerJolien De WynAnneleen BeckersKaren SermonJo VandesompeleFranki SpelemanKatleen De Preter

Glutathione biosynthesis is upregulated at the initiation of MYCN-driven neuroblastoma tumorigenesis

Daniel R CarterSelina K SuttonMarina PajicJayne MurrayEric O SekyereJamie FletcherAnneleen BeckersKatleen De PreterFranki SpelemanRani E George et al.

A1 Journal Article in MOLECULAR ONCOLOGY

MYCN and HDAC5 transcriptionally repress CD9 to trigger invasion and metastasis in neuroblastoma

Johannes FabianDesirée OpitzKristina AlthoffMarco LodriniBarbara HeroRuth VollandAnneleen BeckersKatleen De PreterAnneleen DecockNitin Patil et al.

A1 Journal Article in ONCOTARGET

SOX11 acts as part of the MYCN regulatory protein complex implicated in neuroblastoma

Bieke DecaestekerSara De BrouwerSuzanne VanhauwaertFanny De VloedAnneleen BeckersGenevieve LaureysStein AertsSara EkFranki SpelemanKatleen De Preter

Targeting MYCN-driven transcription by BET-bromodomain inhibition

Anton G HenssenKristina AlthoffAndrea OderskyAnneleen BeckersRichard KocheFranki SpelemanSimon SchaeferEmma BellMaike NortmeyerFrank Westermann et al.

A1 Journal Article in CLINICAL CANCER RESEARCH

The TBX2 super-enhancer marked transcription factor on 17q is overexpressed in neuroblastoma and infers poor prognosis

Bieke DecaestekerAnton HenssenWouter Van LoockeAnneleen BeckersSiebe LoontiensJohannes SchulteKatleen De PreterFranki Speleman

The TBX2 super-enhancer marked transcription factor on 17q is overexpressed in neuroblastoma and infers poor prognosis

Bieke DecaestekerFanny De VloedSiebe LoontiensGeertrui DeneckerWouter Van LoockeMoritz GartlgruberDries RombautAnneleen BeckersShana ClaeysAnton Henssen et al.

The chromosome 17q super-enhancer landscape in neuroblastoma

Bieke DecaestekerAnton HenssenWouter Van LoockeFrancisco Avila CobosAnneleen BeckersStein AertsJohannes SchulteKatleen De PreterFranki Speleman

2015

A Cre-conditional MYCN-driven neuroblastoma mouse model as an improved tool for preclinical studies

Kristina AlthoffAnneleen BeckersEmma BellMaike NortmeyerTheresa ThorAnnika SprüsselSven LindnerKatleen De PreterAlexandra FlorinLukas C Heukamp et al.

A1 Journal Article in ONCOGENE

An embryonic stem cell activated FOXM1 transcriptional program marks ultra-high-risk primary neuroblastoma patients for FDI-6 small molecule inhibition

Suzanne VanhauwaertCarina LeonelliSara De BrouwerJolien De WynAnneleen BeckersNeuroblastoma Research consortiumJo VandesompeleKaren SermonFranki SpelemanKatleen De Preter

Differential module analysis in neuroblastoma regulatory networks

Robrecht CannoodtAnneleen BeckersCaroline Van CauwenberghFranki SpelemanKatleen De PreterYvan Saeys

ETV5 functionally connect ALK and RET signaling in neuroblastoma

Irina LambertzShana ClaeysCandy KumpsLiselot MusAnneleen BeckersEls JanssensNadine Van RoyGenevieve LaureysJohannes SchulteOlivier De Wever et al.

Integrated and cross-species omics analyses identify the DNA damage response pathway as an important vulnerable pathway in aggressive neuroblastoma tumors

Katleen De PreterAnneleen BeckersSuzanne VanhauwaertAnnelies FieuwSara De BrouwerPieter MestdaghJo VandesompeleFranki Speleman

MYCN transcriptionally represses CD9 to trigger an invasion-metastasis cascade in neuroblastoma

H DeubzerJ FabianD OpitzK AlthoffM LodriniK AstrahantseffB HeroR VollandAnneleen BeckersKatleen De Preter et al.

MYCN-driven regulatory mechanisms controlling LIN28B in neuroblastoma

Anneleen BeckersGert Van PeerDaniel R CarterMoritz GartlgruberCarl HerrmannSaurabh AgarwalHetty HelsmoortelKristina AlthoffJan J MolenaarBelamy B Cheung et al.

A1 Journal Article in CANCER LETTERS

MYCN-targeting miRNAs are predominantly downregulated during MYCN-driven neuroblastoma tumor formation

Anneleen BeckersGert Van PeerDaniel R CarterKristina AlthoffBelamy B CheungJohannes H SchultePieter MestdaghJo VandesompeleGlenn M MarshallKatleen De Preter et al.

A1 Journal Article in ONCOTARGET

RNA expression signatures and posttranscriptional regulation in diabetic nephropathy

Michael RudnickiAnneleen BeckersHannes NeuwirtJo Vandesompele

A1 Journal Article in NEPHROLOGY DIALYSIS TRANSPLANTATION

Synergistic combined molecular treatment targeting the HBP1 tumor suppressor gene in neuroblastoma

Shana ClaeysIrina LambertzAlan Van GoethemAnneleen BeckersCandy KumpsTom Van MaerkenJohannes SchulteKatleen De PreterFranki Speleman

Targeting super-enhancer induced gene expression with the novel BRD4 inhibitor OTX015 in preclinical models of MYCN-amplified neuroblastoma

Anton HenssenKristina AlthoffRichard KocheAndrea OderskyAnneleen BeckersFranki SpelemanSimon SchaefersKatleen De PreterAlexandra FlorinLukas Heukamp et al.

The HBP1 tumour suppressor at multiple regulatory cross roads in neuroblastoma

Shana ClaeysIrina LambertzAlan Van GoethemAnneleen BeckersCandy KumpsTom Van MaerkenJohannes SchulteKatleen De PreterFranki Speleman

The chromosome 17q super-enhancer landscape in neuroblastoma

Bieke DecaestekerAnton HenssenWouter Van LoockeAnneleen BeckersStein AertsJohannes SchulteKatleen De PreterFranki Speleman

The chromosome 17q super-enhancer landscape in neuroblastoma

Bieke DecaestekerAnton HenssenWouter Van LoockeAnneleen BeckersStein AertsJohannes SchulteKatleen De PreterFranki Speleman

Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma

Daniel R CarterJayne MurrayBelamy B CheungLaura GambleJessica KoachJoanna TsangSelina SuttonHeyam KallaSarah SyedAndrew J Gifford et al.

A1 Journal Article in SCIENCE TRANSLATIONAL MEDICINE

Unraveling the MYCN-driven transcriptional landscape of neuroblastoma : a cross-species integrated transcriptome approach

Anneleen BeckersFranki SpelemanKatleen De Preter

Upregulation of MAPK negative feedback regulators and RET in mutant ALK neuroblastoma : implications for targeted treatment

Irina LambertzCandy KumpsShana ClaeysSven LindnerAnneleen BeckersEls JanssensDaniel R CarterAlex CazesBelamy B CheungMarilena De Mariano et al.

A1 Journal Article in CLINICAL CANCER RESEARCH

Upregulation of MAPK negative feedback regulators and RET in mutant ALK neuroblastoma : implications for targeted treatment

Irina LambertzCandy KumpsShana ClaeysSven LindnerAnneleen BeckersEls JanssensDaniel CarterAlex CazesBelamy CheungMarilena De Mariano et al.

Upregulation of MAPK negative feedback regulators and RET in mutant ALK neuroblastoma : implications for targeted treatment

Irina LambertzCandy KumpsShana ClaeysSven LindnerAnneleen BeckersEls JanssensDaniel CarterAlex CazesBelamy CheungMarilena De Mariano et al.

Upregulation of MAPK negative feedback regulators and RET in mutant ALK neuroblastoma : implications for targeted treatment

Irina LambertzCandy KumpsShana ClaeysSven LindnerAnneleen BeckersEls JanssensDaniel CarterAlex CazesBelamy CheungMarilena De Mariano et al.

miR-542-3p exerts tumor suppressive functions in neuroblastoma by downregulating Survivin

Kristina AlthoffSven LindnerAndrea OderskyPieter MestdaghAnneleen BeckersSarah KarczewskiJan J MolenaarAnna BohrerShirley KnauerFranki Speleman et al.

A1 Journal Article in INTERNATIONAL JOURNAL OF CANCER

2014

Characterization of ALK driven molecular networks identifies perturbed RET and cholinergic signaling in neuroblastoma

Irina LambertzCandy KumpsShana ClaeysSven LindlerAnneleen BeckersEls JanssensMarilena De MarianoSara De BrouwerJay GibbonsGenevieve Laureys et al.

Differential module analysis in neuroblastoma regulatory networks

Robrecht CannoodtAnneleen BeckersCaroline Van CauwenberghKatleen De PreterYvan Saeys

MYCN safeguards its upregulated expression through negatively controlling its upstream miRNAs

Anneleen BeckersGert Van PeerDaniel CarterBelamy CheungJo VandesompeleGlenn MarshallKatleen De PreterFranki Speleman

Promoter DNA-methylation in the TH-MYCN neuroblastoma mouse model

Anneleen BeckersWouter Van LoockeAnneleen DecockMaté OngenaertJo VandesompeleFranki SpelemanKatleen De Preter

Reduced DICER1 functionality in neuroblastoma through reduced expression levels or somatic mutations

Bram De WildeJohannes H SchulteAnneleen BeckersAlexander SchrammAnnelies FieuwDaniel CarterBelamy CheungGlenn MarshallAngelika EggertKatleen De Preter et al.

SOX11 is a lineage-survival oncogene in neuroblastoma

Bieke DecaestekerSara De BrouwerAnneleen BeckersGenevieve LaureysMonique MorrisonRodney StewartFranki SpelemanKatleen De Preter

SOX11 is a lineage-survival oncogene in neuroblastoma

Bieke DecaestekerSara De BrouwerAnneleen BeckersRodney StewartFranki SpelemanKatleen De Preter

SOX11 is a lineage-survival oncogene in neuroblastoma

Sara De BrouwerBieke DecaestekerAnneleen BeckersGenevieve LaureysMonique MorrisonRodney StewartFranki SpelemanKatleen De Preter

The MYCN/miR-26a-5p/LIN28B regulatory axis controls MYCN-driven LIN28B upregulation in neuroblastoma

Anneleen BeckersAndrew LudwigGert Van PeerDaniel CarterBelamy CheungSara De BrouwerJo VandesompeleKatleen De PreterJason ShohetFranki Speleman

The MYCN/miR-26a-5p/LIN28B regulatory axis explains MYCN driven LIN28B upregulation during mouse neuroblastoma development

Anneleen BeckersDaniel CarterAndrew LudwigGert Van PeerBelamy CheungJo VandesompeleGlenn MarshallJason ShohetKatleen De PreterFranki Speleman

Time-resolved transcriptome analysis of TH-MYCN driven hyperplastic ganglia and tumors marks BRD3 as a novel candidate oncogene

Anneleen BeckersDaniel CarterCheung BelamyJo VandesompeleGlen MarshallKatleen De PreterFranki Speleman

miRBase Tracker : keeping track of microRNA annotation changes

Gert Van PeerSteve LefeverJasper AnckaertAnneleen BeckersAli RihaniAlan Van GoethemPieter-Jan VoldersFjoralba ZekaMaté OngenaertPieter Mestdagh et al.

A1 Journal Article in DATABASE-THE JOURNAL OF BIOLOGICAL DATABASES AND CURATION

2013

BET bromodomain protein inhibition is a therapeutic option for medulloblastoma

Anton HenssenTheresa ThorAndrea OderskyLukas HeukampNicolai El-HindyAnneleen BeckersFranki SpelemanKristina AlthofSimon SchäfersAlexander Schramm et al.

A1 Journal Article in ONCOTARGET

Dynamic regulation of miRNAs implicated in the MYCN-EZH2 regulatory axis during neuroblastoma tumor initiation and progression in a MYCN mouse model

Anneleen BeckersKatleen De PreterBelamy CheungDaniel CarterGert Van PeerSara De BrouwerPieter MestdaghGenevieve LaureysJo VandesompeleGlenn Marshall et al.

Effective Alu repeat based RT-qPCR normalization in cancer cell perturbation experiments

Ali RihaniTom Van MaerkenFilip PattynGert Van PeerAnneleen BeckersSara De BrouwerCandy KumpsEvelien MetsJoni Van der MeulenPieter Rondou et al.

A1 Journal Article in PLOS ONE

Genome wide expression, mutation and methylation analysis validates three new mouse models for neuroblastoma targeting MYCN, ALK and LIN28B for pre-clinical studies

Anneleen BeckersBram De WildeMaté OngenaertCandy KumpsJohannes H SchulteJo VandesompeleKatleen De PreterFranki Speleman

Identification of miRNAs implicated in neuroblastoma tumor initiation and progression through cross-species integrated genomic analysis

Anneleen BeckersKatleen De PreterBelamy CheungSara De BrouwerGert Van PeerPieter MestdaghGenevieve LaureysJo VandesompeleGlenn MarshallFranki Speleman

The MYCN driven murine and human neuroblastoma methylome and dynamic regulation of chromatin regulators as a guide for epigenetic therapy

Anneleen BeckersAnneleen DecockBelamy CheungDaniel CarterGert Van PeerSara De BrouwerGenevieve LaureysJo VandesompeleJohannes H SchulteGlenn Marshall et al.

The need for transparency and good practices in the qPCR literature

Stephen A BustinVladimir BenesJeremy GarsonJan HellemansJim HuggettMikael KubistaReinhold MuellerTania NolanMichael W PfafflGregory Shipley et al.

A1 Journal Article in NATURE METHODS

miR-137 functions as a tumor suppressor in neuroblastoma by downregulating KDM1A

Kristina AlthoffAnneleen BeckersAndrea OderskyPieter MestdaghJohannes KösterIsabella BrayKenneth BryanJo VandesompeleFranki SpelemanRaymond Stallings et al.

A1 Journal Article in INTERNATIONAL JOURNAL OF CANCER

2012

Genomic profiling of MYCN and ALKF1174L transgenic neuroblastoma mouse models provides insights into the dynamic process of tumor formation

Katleen De PreterAnneleen BeckersCandy KumpsPieter MestdaghAngelika EggertJo VandesompeleFranki SpelemanJohannes H Schulte

MiR-137 is epigenetically silenced in MYCN amplified neuroblastoma and targets the polycomb repressive complex 2 (PRC2) component EZH2

Anneleen BeckersMaté OngenaertAnneleen DecockCandy KumpsFilip PattynPieter MestdaghJohannes H. SchulteFranki SpelemanKatleen De Preter

MiR-137 is epigenetically silenced in MYCN amplified neuroblastomas and targets the polycomb repressive complex 2 (PRC2) component EZH2

Anneleen BeckersMaté OngenaertAnneleen DecockCandy KumpsFilip Pattynthe Neuroblastoma Research Consortium (NRC)Pieter MestdaghJohannes H SchulteFranki SpelemanKatleen De Preter